Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This research study was designed to determine the effectiveness of the drug, topotecan, given
intravenously (into a vein) together with the drug gemcitabine in patients with recurrent
platinum-sensitive ovarian, fallopian or primary peritoneal cancer, as well as tumors of
mixed mullerian origin. Additional purposes are to determine the long term outcome and side
effects of this combination treatment.
Since topotecan and gemcitabine have different mechanisms of action, the combination of these
2 drugs may provide better results than either drug alone. Prior studies suggest that the
combination of topotecan and gemcitabine improves the effects on the tumor and also appeared
to be well tolerated.